Gilead Sciences inked a partnership with Assembly Biosciences that will focus on developing antiviral therapies for diseases like herpes, hepatitis B and hepatitis D, the company announced Tuesday.

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its ...

--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10, ...

Assembly Biosciences, Inc. announced positive interim results from its Phase 1a study of ABI-1179, a new oral treatment for recurrent genital herpes, highlighting its favorable safety profile, good ...

– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose ...

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study of ABI-5366, an ...

Gilead Sciences is paying Assembly Biosciences $100 million for first refusal on all Assembly’s programs. The deal comprises $84.8 million in cash, plus $15.2 million in equity investment. Rather than ...

Assembly Bio will receive $100 million, $84.8 million upfront payment and a $15.2 million equity investment, from Gilead. Gilead has the right to appoint two individuals to Assembly Bio's board. Get ...

––Partnership combines Gilead’s proven track record and mission to develop transformative therapeutics targeting serious viral diseases, with Assembly Bio’s expertise and focus on antiviral R&D to ...

– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development ...